Pharmaceutical Executive Daily: Egetis Sells Priority Review Voucher for $190 Million

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, ANI Pharmaceuticals makes a roughly $560 million offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for $190 million, Novartis exits its BrainTransporter deal with BioArctic just 14 months after signing, and Ignite Proteomics’ Dr. Brian Corgiat argues cancer testing needs to capture what’s actively driving a tumor, not just its static mutations.

ANI Pharmaceuticals sent a recommended public offer to acquire Egetis Therapeutics, valuing the rare disease company at approximately $560 million, a 27% premium reflecting an enterprise value of about $434 million. The deal adds Emcitate, the first approved treatment for peripheral thyrotoxicosis in MCT8 deficiency, which ANI estimates could reach more than $300 million in peak sales. Separately, Egetis agreed to sell its Rare Pediatric Disease Priority Review Voucher for $190 million in gross proceeds.

Novartis terminated its collaboration with BioArctic just 14 months after signing an August 2025 deal to pair BioArctic’s BrainTransporter platform with a Novartis antibody targeting neurodegeneration. BioArctic says the exit reflects an internal Novartis portfolio decision unrelated to the platform itself, and will retain the full $30 million upfront payment already received.

Finally, Ignite Proteomics senior clinical research scientist Dr. Brian Corgiat makes the case for phosphoproteome testing to improve how recurrent tumors are evaluated, arguing that genetic and immunohistochemistry tests capture a static picture while missing which proteins are actively driving a tumor at the moment of biopsy. He contends that adding this “snapshot” of active signaling to standard test panels could prevent patients from receiving treatments targeting inactive tumor elements.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.